News Sentiment

PRAX sentiment intelligence

Praxis Precision Medicines Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 58 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 324.99 Week of 10 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

83/100 classification confidence.

Company focus 50

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

+2.0% over one week, +21.9% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Positive

Should Praxis–Remagine Transdermal Patch Collaboration and FDA Review Extension Reshape PRAX Pipeline Expectations?

Market Reaction

Balanced read

66/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 83/100 classification
One-week reaction 2.0% Price confirming higher
Trend fit Trend inactive 21.9% over four weeks
Fair value 207.6% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 20
Neutral 33
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 50
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 12
Stock Titan 10
TradingView 5
simplywall.st 5
Investing.com 4
MT Newswires 4
Simply Wall Street 3
GlobeNewswire 3

Event Lens

What the news is about

Classified themes
Market update 37
Analyst action 9
Earnings 9
Deals and strategy 3

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-58 of 58
Stock Titan Direct company coverage

FDA extends Praxis (NASDAQ: PRAX) relutrigine review deadline to Dec 27, 2026

The FDA has extended the review period for Praxis Precision Medicines' New Drug Application (NDA) for relutrigine by three months, moving the PDUFA target action date to December 27, 2026. This extension occurred because Praxis submitted additional sensitivity analyses of existin

Tone
Negative 42/100
Event
Analyst action
Published
29 Jun 2026 21:10
Source
Stock Titan
Stock Titan Direct company coverage

FDA delays Praxis relutrigine review by three months to Dec. 27

Praxis Precision Medicines announced that the FDA has extended the review period for its New Drug Application (NDA) for relutrigine by three months, shifting the PDUFA target action date from September 27, 2026, to December 27, 2026. This extension is due to a "major amendment" s

Tone
Negative 38/100
Event
Analyst action
Published
29 Jun 2026 20:10
Source
Stock Titan